Tagged with ALS

UK A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in Cambridge; the GBP 17.9 million initiative to boster UK clinical trials, and Obsidian Therapeutics’ USD 160.5 million Series C funding raise.…

Hong Kong Haematological oncologist Dr Raymond Liang, gives his take on the adoption and challenges of CAR-T therapy in Hong Kong, the necessity of collaboration with mainland China for patient referrals and clinical trials, and the evolution of both Hong Kong’s hospital and regulatory infrastructure, which point to a brighter future for…

Europe The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials in the EU by transforming how trials are initiated, designed, and run. In conversation following DIA Europe 2024 in Brussels,…

China Chinese biotech Jacobio has made remarkable strides in pioneering first-in-class drug research, with their SHP2 inhibitor project only the second globally to initiate a clinical trial for a novel target and eventually licensed to AbbVie for approximately USD one billion in 2020. Chairman and CEO Dr Wang Yinxiang outlines Jacobio’sstrategic…

Spain Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is intensifying its commitment to the country with a total investment of EUR 1.3 billion its new global R&D hub in…

Saudi Arabia Mohamed Mostafa explains how PDC-CRO’s successful 2023 was driven by a direct-to-biotech strategy, with the company now well-established as a comprehensive partner for biotech firms across the Gulf and Levant regions. Mostafa also outlines why Saudi Arabia is a key market for PDC-CRO, especially with recent healthcare sector developments and…

India Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened up its clinical research regulations and saw a significant drop in trial numbers. However, with a revised regulatory landscape, a…

MEA Peter Lane lays out IQVIA’s nuanced and ambitious vision for healthcare in the vast AMESA region, focused on empowering smarter healthcare and improving patient outcomes. Lane explains how IQVIA hopes to do this through clinical research, maximizing data value, providing technology and analytics to healthcare systems, and ensuring global health…

France France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such as the National Health Data System contribute to France’s competitiveness, obstacles to further growth remain. In conversation with PharmaBoardroom, Hubert…

India Under the leadership of Ajay Tandon and the foundational work of Dr Kiran Marthak, Indian firm Veeda Clinical Research has strategically expanded its capabilities and global footprint. The company has transitioned from focusing primarily on clinical research to incorporating preclinical services through the acquisition of Bioneeds, aiming to offer end-to-end…

Portugal After achieving the highest sales figures in the affiliate’s history in 2023, general manager of Teva Pharmaceuticals Portugal Marta Gonzalez Casal outlines the restructuring efforts that have taken place in Portugal to strengthen its commercial operations. She also reviews the company’s shift towards innovation and the challenges of Teva’s hospital…

Portugal While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific community, a growing openness to collaboration with industry, and access to a European patient database. Considering the remarkable progress that…